CPT 81439: Hereditary Cardiomyopathy Multigene Sequence Panel
Commercial payers pay $619 on average nationally for this procedure.
CPT code 81439 describes a genomic sequence analysis panel performed by a laboratory analyst to evaluate a patient specimen for nucleotide sequence variants across at least five cardiomyopathy-related genes, used to assess hereditary cardiomyopathies such as hypertrophic, dilated, or arrhythmogenic right ventricular cardiomyopathy; service type: genetic diagnostic testing / multi-gene sequencing panel; typical site of service: clinical laboratory or reference molecular diagnostics lab.
For related coverage guidance, see recent payer policy updates: RTM Testing of Homocysteine Metabolism-Related Conditions, Multimarker Serum Testing Related to Ovarian Cancer, Genomic Profiling for Selecting Targeted Cancer Therapies.
Customize your policy alerts
Sign up for cpt 81439 policy alerts
Get alerted when payer policies referencing 81439 are released or updated.
Monitor payer policy activity
National Reimbursement Benchmarks
For CPT 81439, the commercial market centers around the BUCA average commercial rate of $619.30, with notable variation among major payers. Blue Cross Blue Shield displays the largest spread between its 75th and 25th percentiles at $328.00 ($775.70 - $468.70), followed by Cigna with a spread of $495.70 ($853.40 - $358.70). Aetna shows a more moderate dispersion of $293.10 ($526.40 - $267.30), while UnitedHealth Group is relatively tighter at $322.70 ($584.90 - $256.20). These interquartile spreads highlight meaningful payer-level differences in negotiated commercial pricing.
Looking at central tendency, Cigna and Blue Cross Blue Shield have higher mean rates at $737.00 and $686.20 respectively, while UnitedHealth Group’s mean sits lower at $502.90 and Aetna’s mean is $417.50. BUCA’s mean of $619.30 aligns between those payers, emphasizing BUCA as a mid-to-upper market benchmark. Presence of high maximums (e.g., Cigna $2,885.60; BCBS $2,346.10) further underscores upper-tail variability across commercial contracts.